Zhong Lun Law Firm fields a considerable life sciences and healthcare workload with capabilities spanning the subsectors of new drugs, bioproducts, pharmaceuticals and gene editing, excelling at M&A, restructuring, capital markets and compliance matters. Practice head Changyu Fu is equipped to handle corporate and IP protection issues, as well as disputes involving international commerce, trade and cross-border investments. Shaun Gao is a key figure for complex private equity and venture capital transactions, while Jim Qiu has a particular focus on compliance and risk management for multinational and domestic enterprises. Yuru Zuo leverages her dual background in biology and law when advising biotechnology and pharmaceutical clients.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- ‘Rigorous professional attitude, keen risk awareness and pragmatic solutions.’
- ‘Chunhui Yan has extensive experience in patent litigation, trade secret protection, and licensing. He has successfully handled many difficult intellectual property disputes and provided very valuable advice on intellectual property protection and licensing policies for our emerging technologies.'
- ‘The team is not only deeply involved in law-related majors, but also has a technical background in life sciences, helping to fully control the requirements that our unit needs to pay attention to in the field of life and health when cooperating with third parties.'
- ‘The team has demonstrated excellent professional capabilities and deep industry insights, they are familiar with the Chinese pharmaceutical regulatory system and international compliance standards, and are adept at handling complex legal matters involving drug research and development, production, licensing, post-market management and cross-border transactions.”
- “Chunhui Yan has deep expertise in the field of life sciences and healthcare, demonstrating meticulous legal analysis skills and excellent communication and coordination skills during the service process, and can propose innovative and actionable solutions in a multi-party game environment.”
- ‘The team has a deep understanding of laws, regulations and judicial practice in the fields of intellectual property rights and anti-unfair competition, and can quickly sort out the focus of disputes and provide a variety of rights protection solutions to clarify the direction for follow-up work.”
Key clients
- Tianjing Biotechnology Co., Ltd.
- Foreseen Biotechnology
- Valgen Holding Corporation
- RinuaGene Biotechnology Co., Ltd.
- Carlyle Group
- SynerK Biotechnology Co., Ltd
- LaNova Medicines Technology Co., Ltd.
- Dong-E-E-Jiao Co., Ltd.
- China Resources Biomedical Co., Ltd.
- Lepu Biopharma Co., Ltd.
- HTA Co., Ltd.
- Beijing Neurosurgical Institute
Work highlights
Representing TJ Biopharma in its strategic collaboration with Sanofi regarding the development, manufacturing, and commercialisation of TJ Biopharma’s proprietary globally innovative CD73 antibody, Uliledlimab, in Greater China.
Representing Foreseen Biotechnology, providing legal services for its cell line license, drug development and manufacturing, license out and commercialization of an antibody-drug conjugate (ADC) product.
Representing Valgen Holding Corporation, providing advice on corporate governance matter and assisting the company in handling a series of disputes with shareholders.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Qi Lan
Jim Qiu
Yuru Zuo
Practice head
Helen Cheng; Changyu Fu; Dongmei Wang; Jim Qiu; Shaun Gao
Other key lawyers
Yuru Zuo; Qi Lan, Shuman Zhang; Chunhui Yan